CBD, Nutrient Metabolism and Energy Intake

Not Applicable

Completed

• Conditions: Appetitive Behavior; Glucose Metabolism Disorders (Including Diabetes Mellitus); Lipid Metabolism Disorders
• Interventions: Dietary Supplement: Acute oral CBD supplementation; Dietary Supplement: Acute oral placebo supplementation

• Registration Number: NCT05618756
• Lead Sponsor: Loughborough University

Brief Summary

CBD may affect metabolic control and energy intake. However, there is currently little data regarding these specific outcomes in humans. Therefore, this study will investigate whether a single 300 mg dose of CBD can improve metabolic control following a meal and/or reduce energy intake at a subsequent meal. Healthy, adult volunteers will complete two conditions in a crossover design, comparing outcomes following both CBD and placebo supplementation.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-30
• Study First Submitted: 2022-02-23
• Primary Completion: 2022-04-30
• Study Completion: 2022-04-30
• Study First Submitted QC: 2022-11-09
• Study First Posted: 2022-11-16
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-04
• Last Update Posted: 2025-02-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Self-report as healthy, male or female, aged 18-50, body mass index ≥18.5 and <30.0

Exclusion Criteria

• Currently engage in >10 hours moderate or vigorous intensity physical activity per week
• Have consumed CBD or cannabis at all within the past two months
• Have used CBD or cannabis regularly (>2x in a week) within the past four months
• Are suffering from any clinically significant illness
• Have regularly used tobacco within the previous 6 months (> 2/week)
• Currently use any prescription or over-the-counter medications (except for hormonal contraception and simple painkillers)
• Have given a standard blood donation within 30 days of screening
• Are currently pregnant or lactating
• Are allergic/intolerant to any ingredients in food items provided during the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Cannabidiol	Acute oral CBD supplementation	300 mg CBD (KannaSwiss, Kölliken, Switzerland) dissolved in 1 ml hemp oil. Provided orally in gelatin capsules.
Placebo	Acute oral placebo supplementation	1 ml hemp oil. Provided orally in gelatin capsules.

Primary Outcome Measures

Name	Time	Method
Energy intake	~5-30 minutes (time taken to eat a single meal)	Self-selected energy intake at an ad libitum mixed meal
Postprandial Glycaemia	3 hours	Plasma glucose response to a mixed meal (plasma glucose concentrations and area under curve)
Postprandial Triglyceridaemia	3 hours	Plasma triglyceride response to a mixed meal (plasma triglyceride concentrations and area under curve)

Secondary Outcome Measures

Name	Time	Method
Postprandial Insulinaemia	3 hours	Plasma Insulin response to a mixed meal (plasma insulin concentrations and area under curve)

Trial Locations

Locations (1)

Loughborough University; 🇬🇧 Loughborough, Leicestershire, United Kingdom